GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.
On September 11 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030.
TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
Our resource compendium is a non-exhaustive list of materials covering long-acting technologies to inform the hepatitis C, latent tuberculosis infection, and malaria scope of work under the LONGEVITY Project. Long-Acting Technologies Trials Tracker Illustrated Glossary for Long-Acting Technologies Select Scientific…
The Illustrated Glossary for Long-Acting Technologies compiles frequent terms and concepts used in the research and development of long-acting technologies. The glossary is a non-exhaustive list and the graphics are artistic renderings meant to spur discussion and assist with community treatment literacy.
The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs), home to 75% of those living with this viral illness.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.